H-Index
17
Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
Medical Science Monitor Basic Research

Annals
ISI-Home


Published: 2021-06-18

#930890

Use of Intravenous Hydroxocobalamin without Methylene Blue for Refractory Vasoplegic Syndrome After Cardiopulmonary Bypass

Vincent Peyko, Michael Finamore

USA Department of Pharmacy, Mercy Health – St Elizabeth’s Boardman Hospital, Boardman, OH, USA

Am J Case Rep 2021; 22:e930890

DOI: 10.12659/AJCR.930890


BACKGROUND: Cardiac vasoplegic syndrome is a form of vasodilatory shock characterized by profound vasodilation and low systemic vascular resistance, which results in significant hypotension despite high cardiac output and appropriate fluid resuscitation. In up to 45% of patients, cardiopulmonary bypass (CPB) can precipitate vasoplegic syndrome. Vasoplegic syndrome after CPB that is refractory to other vasopressors, such as catecholamine and vasopressin, has been successfully treated with inhibitors of the nitric oxide (NO) system, such as methylene blue and hydroxocobalamin. Methylene blue has been the treatment of choice because of its effectiveness for both prevention and rescue therapy. Hydroxocobalamin has demonstrated efficacy in combination with methylene blue, and also on its own when vasoplegic syndrome is refractory to methylene blue.
CASE REPORT: We present 2 cases that expand upon the existing evidence supporting the efficacy of hydroxocobalamin as a first-line option for inhibiting the NO system in vasoplegic syndrome that is refractory to other vasopressors. Specifically, we demonstrate the appropriate and successful use of hydroxocobalamin alone to treat refractory vasoplegic syndrome after CPB.
CONCLUSIONS: Refractory vasoplegic syndrome that occurs after CPB has been successfully treated with inhibitors of the NO system, such as methylene blue and hydroxocobalamin. The present cases expand upon the scant existing evidence of the efficacy of hydroxocobalamin as an appropriate option for refractory vasoplegic syndrome.

Keywords: Cardiopulmonary Bypass, Hydroxocobalamin, Methylene Blue, Vasoplegia



Related articles (0)

Coming soon

Published: 2021-06-18
#932241

#932241

SMAD4 Germline Pathogenic Variant-Related Gastric Juvenile Polyposis with Adenocarcinoma Treated with Lap...


Japan Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

Yuya Sakurai, Satoru Kikuchi ORCID logo, Kunitoshi Shigeyasu, Yoshihiko Kakiuchi, Takehiro Tanaka, Hibiki Umeda, Masaki Sakamoto, Sho Takeda, Shuya Yano, Mashu Futagawa, Fumino Kato, Reimi Sogawa, Hideki Yamamoto, Shinji Kuroda, Yoshitaka Kondo, Fuminori Teraishi, Hiroyuki Kishimoto, Masahiko Nishizaki, Shunsuke Kagawa, Akira Hirasawa, Toshiyoshi Fujiwara

Am J Case Rep 2021; 22:e932241

DOI: 10.12659/AJCR.932241

Published: 2021-06-17
#932321

#932321

SARS-CoV-2-Related Subacute Thyroiditis, Myocarditis, and Hepatitis After Full Resolution of COVID-19 Ser...


Mexico Department of Biochemistry and Medicine, La Salle University School of Medicine, Mexico City, Mexico

Alejandra Osorio Martínez, Victoria Taís González-Razo, Valeria Navarro-Sánchez, Carlos A. Souto Meiriño, Miguel Ahumada-Ayala

Am J Case Rep 2021; 22:e932321

DOI: 10.12659/AJCR.932321